Publications by authors named "Lena E D'Hooghe"
Article Synopsis
- Rozanolixizumab (UCB7665) is a monoclonal antibody designed to target and reduce harmful IgG antibodies in autoimmune and alloimmune diseases by inhibiting the neonatal Fc receptor (FcRn).
- Studies show that this antibody effectively lowers plasma IgG levels in animal models (mice and cynomolgus monkeys) without affecting albumin levels and demonstrates a good safety profile during prolonged administration.
- Current research includes clinical trials for conditions like immune thrombocytopenia and myasthenia gravis, suggesting rozanolixizumab could be a promising new treatment option for these diseases.
The stability of therapeutic antibodies is a prime pharmaceutical concern. In this work we examined thermal stability differences between human IgG1 and IgG4 Fab domains containing the same variable regions using the thermofluor assay. It was found that the IgG1 Fab domain is up to 11°C more stable than the IgG4 Fab domain containing the same variable region.
View Article and Find Full Text PDF